{
    "nctId": "NCT01437865",
    "briefTitle": "Gadofosveset for Axillary Staging in Breast Cancer Patients",
    "officialTitle": "Non-invasive Nodal Staging in Breast Cancer With MRI Lymphography Using Gadofosveset; a Pilot-study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "The accuracy (sensitivity, specificity, NPV and PPV) of the MRI in predicting the involvement of metastases",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patient with histopathologically confirmed invasive breast cancer about to undergo nodal staging.\n2. Tumor must be a T2 according the TNM 6-classification.\n3. The ultrasound of the axilla must be suspect for nodal metastases.\n4. Willing and able to undergo all study procedures\n5. Has personally provided written informed consent.\n\nExclusion Criteria:\n\n1. Age \\<18\n2. History of prior chemotherapy\n3. History of prior radiotherapy of the surrounding areas of the axilla.\n4. Pregnancy\n5. Contra indications for MRI such as pacemaker, aneurysm clips or severe claustrophobia.\n6. Allergy to any of the ingredients of Gadofosveset (Vasovist\u00ae /Ablavar\u00ae)\n7. Being unable to give informed consent in person\n8. Acute or chronic severe renal insufficiency (glomerular filtration rate \\<30 mL/min/1.73m2).\n9. Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}